首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Molecular Mechanism of Yisui Shengxue Granule a Complex Chinese Medicine on Thalassemia Patients Suffering from Hemolysis and Anemia of Erythrocytes
【2h】

Molecular Mechanism of Yisui Shengxue Granule a Complex Chinese Medicine on Thalassemia Patients Suffering from Hemolysis and Anemia of Erythrocytes

机译:中药益遂生血颗粒对红细胞贫血贫血的地中海贫血患者的分子机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of this study was to investigate the therapeutic biological mechanism of Yisui Shengxue Granule (YSSXG), a complex Chinese medicine, on the hemolysis and anemia of erythrocytes from patient with thalassemia disease. Sixteen patients with thalassemia (8 cases of α-thalassemia and 8 cases of β-thalassemia) disease were collected and treated with YSSXG for 3 months. The improvements of blood parameter demonstrated that YSSXG had a positive clinical effect on patients with thalassemia disease. For patients with α-thalassemia disease, RT-PCR showed that YSSXG upregulated the relative mRNA expression level of α-globin to β-globin and downregulated DNMT1, DNMT3a, and DNMT3b mRNA compared with pretreatment. Western blotting showed that YSSXG downregulated the expression of DNMT1 and DNMT3a. For patients with β-thalassemia disease, the relative expression level of A γ-globin to α-globin had an increasing trend and the level of BCL11A mRNA expression obviously increased. For all patients, RT-PCR showed that YSSXG upregulated mRNA expression of SPTA1 and SPTB. Activities of SOD and GSH-Px significantly increased and MDA obviously reduced on erythrocyte and blood serum after YSSXG treatment. TEM showed that YSSXG decreased the content of inclusion bodies. Activities of Na+K+-ATPtase and T-ATPtase of erythrocyte increased significantly after YSSXG treatment. This study provides the basis for mechanisms of YSSXG on thalassemia suffering with hemolysis and anemia of erythrocytes from patient.
机译:这项研究的目的是探讨中药益遂生血颗粒(YSSXG)对地中海贫血患者红细胞溶血和贫血的治疗生物学机制。收集16例地中海贫血患者(8例α-地中海贫血和8例β-地中海贫血)疾病,并用YSSXG治疗3个月。血液参数的改善表明,YSSXG对地中海贫血患者具有积极的临床效果。 RT-PCR显示,对于α地中海贫血患者,与预处理相比,YSSXG上调了α-球蛋白对β-球蛋白的相对mRNA表达水平,并下调了DNMT1,DNMT3a和DNMT3b mRNA的表达。蛋白质印迹显示YSSXG下调了DNMT1和DNMT3a的表达。 β地中海贫血患者中, A γ-球蛋白与α-球蛋白的相对表达水平呈上升趋势,BCL11A mRNA表达水平明显升高。对于所有患者,RT-PCR显示YSSXG上调SPTA1和SPTB的mRNA表达。 YSSXG处理后,红细胞和血清中SOD和GSH-Px的活性显着增加,MDA明显降低。 TEM显示YSSXG降低了包涵体的含量。 YSSXG处理后,红细胞Na + K + -ATP酶和T-ATP酶的活性明显增加。该研究为YSSXG治疗地中海贫血,红细胞贫血,溶血和贫血的机制提供了依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号